The latter only happens in the presence of another specific defect, in this case, a defect in a DNA repair gene, and is best exemplified with the use of PARP inhibitors in cancer cells carrying defects in BRCA1 or BRCA2 genes [172]. This evidence concerns the gene BRCA2 and cancer.